Circulation

JANUARY 24, 2024

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

Heart Disease 81

Heart Disease Strokes Stroke Peripheral Arterial Disease 81

Circulation

NOVEMBER 11, 2024

Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among Results:Among 5002 (projected to 34.0

Diabetes 40

Diabetes Blood Pressure Myocardial Infarction Kidney Disease 40

DAIC

DECEMBER 8, 2023

AFib causes a variety of symptoms, including fast or chaotic heartbeat, fatigue, shortness of breath, and chest pain, and causes about 450,000 hospitalizations each year, according to the Centers for Disease Control and Prevention. For example, kidney disease is not included in CHA 2 DS 2 -VASc.

Atrial Fibrillation 52

Atrial Fibrillation AFIB Strokes Stroke 52

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

DAIC

APRIL 22, 2025

tim.hodson Tue, 04/22/2025 - 09:55 April 22, 2025 Research teams from Augusta University, Massachusetts General Hospital and The Ohio State University will lead a $15 million project dedicated to studying the various ways that risk factors for cardiovascular and kidney diseases impact women.

Research 52

Research Blood Pressure Risk Factors Kidney Disease 52

Dr. Paddy Barrett

JULY 5, 2024

We do a terrible job of identifying and managing high blood pressure. And we still do an awful job of identifying and managing high blood pressure. As a risk factor for death, high blood pressure is responsible for more deaths than any other risk factor, including smoking. What Is Normal Blood Pressure?

Blood Pressure 105

Blood Pressure Heart Attack Heart attacks Risk Factors 105

DAIC

JANUARY 19, 2024

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure. This leaves a gap in the care of these patients and increases their risk for heart attack, stroke and heart failure progression.

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

CardiacWire

OCTOBER 6, 2024

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), blocking the mineralocorticoid receptor and its blood pressure effects. Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF.

Heart Failure 59

Heart Failure Blood Pressure Kidney Disease Diabetes 59

Dr. Paddy Barrett

NOVEMBER 1, 2024

Death from heart disease: 51% reduction in risk. High Blood Pressure: 37% reduction in risk. Heart Failure: 69% reduction in risk. Kidney Disease: 42% reduction in risk. Death from any cause: 53% reduction in risk. Cancer deaths: 43% reduction in risk. Dementia: 64% reduction in risk.

Exercise 118

Exercise Heart Disease Quality of Life Blood Pressure 118

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

Physiologically Speaking

DECEMBER 15, 2023

Effects of resistance training on traditional CVD risk factors Blood pressure Resistance exercise training has been shown to improve resting blood pressure in cohorts of healthy adults and adults with varying levels of high blood pressure.

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

Physiologically Speaking

DECEMBER 15, 2023

Effects of resistance training on traditional CVD risk factors Blood pressure Resistance exercise training has been shown to improve resting blood pressure in cohorts of healthy adults and adults with varying levels of high blood pressure.

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Circulation

NOVEMBER 11, 2024

Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure. vs 5.4%), and hospitalization for heart failure (RR 0.66; 95% CI [0.58, 0.76]; P < 0.00001; 3.2%

Myocardial Infarction 40

Myocardial Infarction Blood Pressure Heart Failure Kidney Disease 40

Circulation

NOVEMBER 11, 2024

Introduction:High levels of blood pressure (BP) are responsible for 7.6 The diagnosis of hypertension is associated with a significant increase in the risk of kidney or cardiovascular events, with no prior history of these events. The AAMR for hypertensive heart and renal disease with heart failure was 0.1

Hypertension 40

Hypertension Heart Failure Certification Heart Disease 40

Cardiometabolic Health Congress

DECEMBER 7, 2023

AF is associated with an increased risk of death as well as multiple adverse outcomes, including stroke, cognitive impairment or dementia, myocardial infarction, sudden cardiac death, heart failure (HF), chronic kidney disease (CKD), and peripheral artery disease (PAD).

Atrial Fibrillation 111

Atrial Fibrillation Risk Factors Ablation Strokes 111

Frontiers in Cardiovascular Medicine

JANUARY 5, 2025

IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) 7,054.0)] pg/ml.

Heart Failure 52

Heart Failure Kidney Disease Blood Pressure Diabetes 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103